NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q4 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- −3 vs. Q3 2023
- Shares held
- 61.9M
- +11.7M (+23.4%) vs. Q3 2023
- Total value
- $691.4M
- +$227.3M (+49.0%) vs. Q3 2023
- New holders
- 4
- 9 more added
- Sold out
- 7
- 5 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DuPont Capital Management Corp | 1 | $11 | 0.00% | 00.0% | Unchanged |
| Atticus Wealth Management, LLC | 100 | $1.12K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 300 | $3.35K | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 500 | $5.00K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 513 | $5.73K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 800 | $8.94K | 0.00% | +800 | New |
| Wolverine Asset Management LLC | 8,694 | $97.1K | 0.00% | +5,769+197.2% | Added |
| Venture Visionary Partners LLC | 10,000 | $111.7K | 0.01% | 00.0% | Unchanged |
| Royal Bank of Canada | 10,875 | $121.0K | 0.00% | +9,875+987.5% | Added |
| Citadel Advisors LLC | 21,046 | $235.1K | 0.00% | −10,351−33.0% | Reduced |
| BlackRock Inc. | 22,941 | $256.3K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 28,538 | $318.8K | 0.00% | +26,836+1,576.7% | Added |
| Marshall Wace, LLP | 33,941 | $379.1K | 0.00% | +23,777+233.9% | Added |
| Geode Capital Management, LLC | 47,324 | $528.6K | 0.00% | +5,516+13.2% | Added |
| Schonfeld Strategic Advisors LLC | 66,900 | $747.3K | 0.01% | +2,200+3.4% | Added |
| Affinity Asset Advisors, LLC | 125,000 | $1.40M | 0.28% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 191,956 | $2.14M | 0.00% | −245,777−56.1% | Reduced |
| Opaleye Management Inc. | 265,388 | $2.96M | 0.80% | +265,388 | New |
| AXA S.A. | 276,328 | $3.09M | 0.01% | −6,687−2.4% | Reduced |
| Parkman Healthcare Partners LLC | 300,750 | $3.36M | 0.48% | +51,726+20.8% | Added |
| Eversept Partners, LP | 374,404 | $4.18M | 0.41% | −286,214−43.3% | Reduced |
| Adage Capital Partners GP, L.L.C. | 1,300,000 | $14.5M | 0.03% | +100,000+8.3% | Added |
| Millennium Management LLC | 1,326,103 | $14.8M | 0.01% | +281,319+26.9% | Added |
| GMT Capital Corp | 1,383,800 | $15.5M | 0.58% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 1,384,321 | $15.5M | 0.00% | +1,384,321 | New |
| BVF Inc | 1,521,948 | $17.0M | 0.43% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $32.1M | 10.82% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 7,864,000 | $87.8M | 1.37% | −1,136,000−12.6% | Reduced |
| Viking Global Investors LPSuperinvestorViking Global Investors | 8,024,565 | $89.6M | 0.33% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $117.0M | 11.21% | 00.0% | Unchanged |
| FCPM III Services B.V. | 11,831,461 | $132.2M | 38.94% | +11,831,461 | New |
| Frazier Life Sciences Management, L.P. | 12,131,705 | $135.5M | 7.25% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −434,912−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −44,432−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Parkwood LLC | 0 | $0 | 0.00% | −20,209−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −13,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −2,622−100.0% | Sold out |